Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation
- PMID: 10655067
- DOI: 10.1038/72855
Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation
Abstract
Osteoclasts are bone-resorbing cells derived from haematopoietic precursors of the monocyte-macrophage lineage. Mice lacking Fos (encoding c-Fos) develop osteopetrosis due to an early differentiation block in the osteoclast lineage. c-Fos is a component of the dimeric transcription factor activator protein-1 (Ap-1), which is composed mainly of Fos (c-Fos, FosB, Fra-1 and Fra-2) and Jun proteins (c-Jun, JunB and JunD). Unlike Fra-1 (encoded by Fosl1), c-Fos contains transactivation domains required for oncogenesis and cellular transformation. The mechanism by which c-Fos exerts its specific function in osteoclast differentiation is not understood. Here we show by retroviral-gene transfer that all four Fos proteins, but not the Jun proteins, rescue the differentiation block in vitro. Structure-function analysis demonstrated that the major carboxy-terminal transactivation domains of c-Fos and FosB are dispensable and that Fra-1 (which lacks transactivation domains) has the highest rescue activity. Moreover, a transgene expressing Fra-1 rescues the osteopetrosis of c-Fos-mutant mice in vivo. The osteoclast differentiation factor Rankl (also known as TRANCE, ODF and OPGL; refs 8-11) induces transcription of Fosl1 in a c-Fos-dependent manner, thereby establishing a link between Rank signalling and the expression of Ap-1 proteins in osteoclast differentiation.
Similar articles
-
Role of heterodimerization of c-Fos and Fra1 proteins in osteoclast differentiation.Bone. 2007 Apr;40(4):867-75. doi: 10.1016/j.bone.2006.11.005. Epub 2006 Dec 26. Bone. 2007. PMID: 17189721
-
Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.Biochem Biophys Res Commun. 2005 Apr 15;329(3):839-45. doi: 10.1016/j.bbrc.2005.02.049. Biochem Biophys Res Commun. 2005. PMID: 15752732
-
Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.J Cell Physiol. 2004 Oct;201(1):17-25. doi: 10.1002/jcp.20041. J Cell Physiol. 2004. PMID: 15281085
-
c-fos and bone loss: a proto-oncogene regulates osteoclast lineage determination.Bioessays. 1995 Apr;17(4):277-81. doi: 10.1002/bies.950170402. Bioessays. 1995. PMID: 7741720 Review.
-
Fos family members: regulation, structure and role in oncogenic transformation.Histol Histopathol. 2000 Jul;15(3):921-8. doi: 10.14670/HH-15.921. Histol Histopathol. 2000. PMID: 10963134 Review.
Cited by
-
Dysregulation of Mitochondrial Functions and Osteogenic Differentiation in Cisd2-Deficient Murine Induced Pluripotent Stem Cells.Stem Cells Dev. 2015 Nov 1;24(21):2561-76. doi: 10.1089/scd.2015.0066. Epub 2015 Aug 10. Stem Cells Dev. 2015. PMID: 26230298 Free PMC article.
-
Specificity of RGS10A as a key component in the RANKL signaling mechanism for osteoclast differentiation.J Cell Sci. 2007 Oct 1;120(Pt 19):3362-71. doi: 10.1242/jcs.008300. J Cell Sci. 2007. PMID: 17881498 Free PMC article.
-
Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system.Osteoporos Int. 2005 Dec;16(12):2180-4. doi: 10.1007/s00198-005-1858-8. Epub 2005 Jun 28. Osteoporos Int. 2005. PMID: 15983730
-
BHLHE40 promotes osteoclastogenesis and abnormal bone resorption via c-Fos/NFATc1.Cell Biosci. 2022 May 26;12(1):70. doi: 10.1186/s13578-022-00813-7. Cell Biosci. 2022. PMID: 35619122 Free PMC article.
-
Soft coral-derived Aspernolide A suppressed non-small cell lung cancer induced osteolytic bone invasion via the c-Fos/NFATC1 signaling pathway.J Thorac Dis. 2021 Oct;13(10):5996-6011. doi: 10.21037/jtd-21-1631. J Thorac Dis. 2021. PMID: 34795947 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous